BLOMSTEIN has successfully advised Teva on its Licensing Collaboration with MODAG


BLOMSTEIN has successfully advised Teva Pharmaceutical Industries Limited (Teva) on the German foreign direct investment aspects of its strategic licensing collaboration with MODAG GmbH (MODAG).

MODAG is a German biotech company which is focussed on the development of ther-apeutics and diagnostics for neurodegenerative diseases. Teva is an Israeli multinational pharmaceutical company specialised in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Under the licensing collaboration and pending regulatory approval, Teva will receive an exclusive global license to develop, manufacture and commercialize MODAG’s compounds anle138b and sery433 for the multiple system atrophy (MSA) and Parkinson’s disease (PD) indications. Any development will be based on early-stage clinical studies and will consider exploring additional indications based on clinical outcomes.

BLOMSTEIN has advised Teva together with Goodwin Procter LLP. The team on our side consisted of Roland M. Stein, Leonard von Rummel, Bruno Galvão and Vanessa Kassem. Many thanks to the whole Goodwin-Team for the pleasant and successful cooperation!

back to overview